Dexcom Inc. Stock
€61.60
Your prediction
Financial data and news for DexCom
sharewise wants to provide you with the best news and tools for DexCom, so we directly link to the best financial data sources.
Financials
News
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Key Points
- Interested in Teladoc Health, Inc.? Here are five stocks we like better.
- With the GLP-1 agonist market still growing at a rapid pace, companies outside of the pharma industry are
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for
Pediatrix Medical Group Q1 Earnings Call Highlights
Pediatrix Medical Group (NYSE:MD) reaffirmed its full-year 2026 adjusted EBITDA outlook after reporting what management described as a strong first quarter, supported
3 Reasons Analysts Love DexCom
While GLP-1 agonists have grabbed investor attention for their potential as weight loss aids, these medicines also form a crucial component of a broader set of tools to address type 2 diabetes
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
Diabetes management is evolving rapidly as the industry innovates to treat the more than 40 million Americans with type 1 or type 2 diabetes. Deciding between two leaders in monitoring and
2 Growth Stocks to Hold for the Next Decade
Over the past year, Intuitive Surgical (NASDAQ: ISRG) and DexCom (NASDAQ: DXCM) have faced headwinds, and have lagged the stock market as a result. Shares of the former are down 13% over the
Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars
Many pharmaceutical companies are looking to develop and market the now highly popular GLP-1 drugs, which help treat diabetes, help patients lose weight, and reduce their risk of a range of